Abbott Laboratories 2022 Q3 Form 10-Q Summary
Business context and reporting period
Abbott Laboratories filed an unaudited Form 10-Q for the quarter and nine months ended September 30, 2022. The company operates through four reportable segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. Results are compared with the corresponding 2021 periods.
Key financial metrics
| Metric | Q3 2022 | Q3 2021 | 9M 2022 | 9M 2021 |
|---|---|---|---|---|
| Net sales | $10.410B | $10.928B | $33.562B | $31.607B |
| Operating earnings | $1.770B | $2.546B | $7.058B | $6.047B |
| Net earnings | $1.435B | $2.100B | $5.900B | $5.082B |
| Diluted EPS | $0.81 | $1.17 | $3.32 | $2.83 |
| Gross margin | 50.7% | 54.8% | 52.1% | 51.6% |
| Operating margin | 17.0% | 23.3% | 21.0% | 19.1% |
| Net margin | 13.8% | 19.2% | 17.6% | 16.1% |
Net cash from operating activities was $7.255 billion for the first nine months, down from $7.466 billion in the prior-year period. Capital expenditures were $1.167 billion, dividends paid were $2.486 billion, and share repurchases were $3.110 billion. Cash and cash equivalents were $9.594 billion at September 30, 2022, versus $9.799 billion at December 31, 2021.
Total debt was approximately $16.414 billion at September 30, 2022, compared with $18.050 billion at year-end 2021. Current and long-term debt were $1.117 billion and $15.297 billion, respectively. Abbott reported $5.0 billion of available credit lines expiring in 2025, investment-grade ratings of AA- from S&P and A1 from Moody’s, and approximately $3.116 billion remaining under its 2021 share-repurchase authorization.
Material changes versus prior comparable periods
- Third-quarter sales declined 4.7% reported but increased 1.3% excluding foreign exchange. The stronger U.S. dollar reduced total sales by 6.0%.
- Nine-month sales increased 6.2% reported and 10.9% excluding foreign exchange, primarily due to COVID-19 diagnostic testing demand and growth in Medical Devices and Established Pharmaceutical Products.
- Q3 operating earnings declined 30.5% and net earnings declined 31.7%; diluted EPS fell 30.8%. For the nine months, operating earnings increased 16.7%, net earnings increased 16.1%, and diluted EPS increased 17.3%.
- Q3 gross margin fell 410 basis points, reflecting the infant-formula recall and Sturgis facility stoppage, WIC-related product prioritization, higher manufacturing and supply-chain costs, lower COVID-19 testing sales, and the nonrecurrence of a favorable 2021 restructuring estimate. Nine-month gross margin improved 50 basis points because of higher rapid-test sales and the nonrecurrence of 2021 restructuring charges.
- Nine-month Diagnostic Products sales increased 18.9% reported and 23.1% excluding foreign exchange, while Medical Devices sales increased 3.0% reported and 8.4% excluding foreign exchange. Established Pharmaceutical Products increased 5.2% reported, while Nutritional Products declined 9.8%.
- FreeStyle Libre sales were $3.1 billion for the nine months, up 22.8% excluding foreign exchange. COVID-19 testing-related sales were approximately $7.3 billion, compared with $5.4 billion in the prior-year period.
- Working capital increased to $11.5 billion from $11.1 billion, primarily because of higher inventories. Inventory increased to $5.734 billion from $5.157 billion at year-end 2021.
Guidance, outlook, commentary, risks, and unusual items
The filing does not provide a clear quantitative earnings or revenue guidance figure. Management stated that the future effects of the COVID-19 pandemic remain uncertain and that inflation, supply-chain disruption, and unfavorable foreign exchange rates could materially affect results.
- Abbott voluntarily recalled certain infant powder formulas in February 2022 and stopped production at its Sturgis, Michigan facility. Partial production restarted in July 2022 after a May 2022 FDA consent decree. U.S. pediatric nutritional sales declined 31.7% for the first nine months; recalled-brand formula sales were $277 million versus $900 million in the prior-year period.
- Third-quarter research and development expense included a $111 million impairment charge for certain medical-device in-process R&D intangible assets.
- The company recorded approximately $172 million of nine-month charges related to the nutritional-product recall and $12 million of restructuring charges. A $13 million restructuring accrual remained at September 30 for the earlier COVID-19 diagnostic manufacturing-network plan, and $34 million remained for other restructuring activities.
- Remaining performance obligations were approximately $3.9 billion in Diagnostics and $433 million in Medical Devices. Abbott expects to recognize approximately 60% over the next 24 months and 16% over the subsequent 12 months.
- Legal and environmental proceedings had an estimated possible loss range of approximately $40 million to $50 million, with a recorded accrual of approximately $45 million. Management did not expect these matters to have a material adverse effect, although outcomes remain uncertain.
- Abbott estimated that gross unrecognized tax benefits could decrease by approximately $75 million to $100 million within the next 12 months as tax matters are resolved.
- The company declared quarterly dividends of $0.47 per share in each of the first three quarters, up from $0.45 per share in the comparable 2021 periods.
Investor verification checklist
- Verify the sustainability of revenue and earnings as COVID-19 diagnostic testing demand declines.
- Track the recovery of U.S. pediatric nutrition sales, the Sturgis facility’s production, recall-related costs, and regulatory compliance.
- Assess gross-margin effects from inflation, commodities, distribution costs, supply constraints, and product mix.
- Reconcile reported versus foreign-exchange-adjusted growth, particularly in international markets.
- Monitor inventory levels and working-capital investment relative to operating cash flow.
- Review debt maturities, interest-rate exposure, share repurchases, dividend commitments, and remaining liquidity.
- Evaluate the potential effect of litigation, tax examinations, contingent consideration, restructuring, and intangible-asset impairments.